Evidence map›Paper›PMID 25642763›Full record

Trial reportBone marrow transplantation2015

Older recipient age is paradoxically associated with a lower incidence of chronic GVHD in thymoglobulin recipients: a retrospective study exploring risk factors for GVHD in allogeneic transplantation with thymoglobulin GVHD prophylaxis.

A B M Lim, J Storek, A Beligaswatte, M Collins, M Tacey, T Williamson, K Mason, E Li, M A Chaudhry, J A Russell and 4 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

A B M Lim1] Department of Clinical Haematology & Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia [2] Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
J StorekDepartment of Oncology, University of Calgary, Calgary, Alberta, Canada.
A BeligaswatteDepartment of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
M CollinsCentre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
M TaceyMelbourne EpiCentre, Parkville, Victoria, Australia.
T WilliamsonDepartment of Oncology, University of Calgary, Calgary, Alberta, Canada.
K MasonDepartment of Clinical Haematology & Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
E LiDepartment of Clinical Haematology & Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
M A ChaudhryDepartment of Oncology, University of Calgary, Calgary, Alberta, Canada.
J A RussellDepartment of Oncology, University of Calgary, Calgary, Alberta, Canada.
A DalyDepartment of Oncology, University of Calgary, Calgary, Alberta, Canada.
J Szer1] Department of Clinical Haematology & Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia [2] Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
I LewisDepartment of Haematology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
D Ritchie1] Department of Clinical Haematology & Bone Marrow Transplant Service, The Royal Melbourne Hospital, Parkville, Victoria, Australia [2] Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
University of Calgary · CAThe Royal Melbourne Hospital · AURoyal Adelaide Hospital · AUUniversity of Melbourne · AUParks Victoria · AUPeter MacCallum Cancer Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thymoglobulin (TG) given with conditioning for allogeneic haematopoietic SCT (alloHSCT) is effective in reducing the risk of acute and chronic GVHD (cGVHD). Whether conventional risk factors for GVHD apply to TG-conditioned alloHSCT is unknown. We retrospectively studied 356 adults from three centres who received TG 4.5 mg/kg prior to alloHSCT for haematologic malignancy. Donors were unrelated in 64%. At 3 years, OS was 61% (95% confidence interval (CI) 55-67%), cumulative incidence of relapse was 28% (95% CI 23-33%) and non-relapse mortality was 19% (14-24%). The cumulative incidences of grade 2-4, and grade 3-4 acute GVHD were 23% (95% CI 19-28%) and 10% (95% CI 6-13%), respectively. The cumulative incidence of cGVHD requiring systemic immunosuppression (cGVHD-IS) at 3 years was 32% (95% CI 27-37%). On multivariate analysis, counterintuitively, recipient age over 40 was associated with a significantly decreased risk of cGVHD-IS (P=0.001). We report for the first time a paradoxical association of older age with reduced cGVHD in TG recipients, and conclude that traditional risk factors for GVHD may behave differently in the context of pre-transplant TG.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAgedAge FactorsAllograftsAntilymphocyte SerumChronic DiseaseDisease-Free SurvivalFemaleGraft vs Host DiseaseHumansIncidenceMaleMiddle AgedRetrospective StudiesAntilymphocyte Serumthymoglobulin

Identifiers

PMID25642763
OpenAlexW2061728539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.